ProfileGDS5678 / 1418135_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 82% 80% 81% 85% 83% 80% 82% 81% 80% 81% 80% 80% 81% 81% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 15.8774682
GSM967853U87-EV human glioblastoma xenograft - Control 25.7422380
GSM967854U87-EV human glioblastoma xenograft - Control 35.7425581
GSM967855U87-EV human glioblastoma xenograft - Control 46.5142585
GSM967856U87-EV human glioblastoma xenograft - Control 56.1342983
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 15.5222580
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 25.744682
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 35.7077681
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 45.6716180
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 15.8362581
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 25.6599180
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 35.7544780
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 45.7250881
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 55.7049381